ABSTRACT
This study was aimed to investigate the correlation between circulating myeloma cells (CMC) and bone marrow myeloma cells (MMC) in patients with multiple myeloma (MM) and its clinical significance. Four-color flow cytometry was used to detect the percentage of CMC and MMC in 55 patients with MM. Other prognosis-associated factors such as beta(2) microglobulin (beta(2)-MG), serum albumin (Alb), chromosomal abnormalities and renal function were simultaneously analyzed. The patients were divided into four groups: group A, in which CMC and MMC were simultaneously detected; group B, in which only MMC were detected; group C, in which only CMC were detected; group D, in which no myeloma cells were detected in peripheral blood or bone marrow. The results showed that the concentrations of beta(2)-MG and creatinine were significantly increased and Alb markedly decreased in group A as compared with other groups. Statistical differences existed in the above-mentioned factors between patients with myeloma cells detected and not detected. The percentages of CMC or MMC in newly diagnosed, refractory and relapsed patients were apparently higher than those in patients with partial and complete remission, respectively. CMC were strikingly correlated with MMC. It is concluded that the percentages of CMC and MMC not only imply tumor load in MM patients, but also predict the progression of MM, respectively for patients with MM, in those patients CMC and MMC were simultaneously detected.
Subject(s)
Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , B-Lymphocytes , Allergy and Immunology , Pathology , Bone Marrow , Pathology , Multiple Myeloma , Blood , Drug Therapy , Pathology , Neoplasm, Residual , Neoplastic Cells, Circulating , Pathology , Plasma Cells , Pathology , PrognosisABSTRACT
The study was aimed to investigate the different prognosis of acute myeloid leukemia (AML) with inv (16). A 13-year-old patient diagnosed as M4Eo presenting with bulky lymphadenopathy was reported, the curative process of patients was presented and the related issues were discussed. The karyotype and inv (16) were detected by conventional cytogeneties and fluorescence in situ hybridization (FISH), respectively, the immunophenotype was detected by flow cytometry. The results showed that conventional cytogenetics and FISH analysis revealed inv (16). Induction therapy included idarubicin and cytarabine. After complete remission, patient received consolidation theray containing high-dose cytarabine (HDAC). FISH analysis revealed poor response of patient to HDAC. It is concluded that bulky lymphadenopathy in AML with inv (16) may be a negative prognostic sign. FISH for inv (16) is specific and constitutes an reliable tool to be used for diagnosis and minimal residual disease (MRD).